These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 19474056

  • 21. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 22. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 23. Characterization of an ambulatory population with stable coronary artery disease and importance of heart rate: the PULSAR registry.
    Seabra-Gomes R, Investigadores do Registo PULSAR.
    Rev Port Cardiol; 2010 Apr 15; 29(4):483-508. PubMed ID: 20734572
    [Abstract] [Full Text] [Related]

  • 24. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb 15; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

  • 25. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.
    Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G.
    Anesth Analg; 2008 Apr 15; 106(4):1039-48, table of contents. PubMed ID: 18349171
    [Abstract] [Full Text] [Related]

  • 26. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G.
    Adv Ther; 2010 Mar 15; 27(3):160-7. PubMed ID: 20419486
    [Abstract] [Full Text] [Related]

  • 27. Heart rate as independent prognostic factor for mortality in normotensive hemodialysed patients.
    Cice G, Di Benedetto A, D'Andrea A, D'Isa S, De Gregorio P, Marcelli D, Gatti E, Calabrò R.
    J Nephrol; 2008 Mar 15; 21(5):704-12. PubMed ID: 18949725
    [Abstract] [Full Text] [Related]

  • 28. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators.
    Lancet; 2008 Sep 06; 372(9641):807-16. PubMed ID: 18757088
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments.
    Kaplinsky E, Comes FP, Urondo LS, Ayma FP.
    Cardiol J; 2010 Sep 06; 17(2):166-71. PubMed ID: 20544616
    [Abstract] [Full Text] [Related]

  • 30. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
    Di Franco A, Sarullo FM, Salerno Y, Figliozzi S, Parrinello R, Di Pasquale P, Lanza GA.
    Am J Cardiovasc Drugs; 2014 Apr 06; 14(2):101-10. PubMed ID: 24327100
    [Abstract] [Full Text] [Related]

  • 31. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct 06; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 32. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 33. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators.
    Lancet; 2008 Sep 06; 372(9641):817-21. PubMed ID: 18757091
    [Abstract] [Full Text] [Related]

  • 34. The benefits of ivabradine are independent of resting heart rate.
    Riccioni G.
    Future Cardiol; 2013 May 06; 9(3):313-5. PubMed ID: 23668736
    [Abstract] [Full Text] [Related]

  • 35. Predicting maximum heart rate among patients with coronary heart disease receiving beta-adrenergic blockade therapy.
    Brawner CA, Ehrman JK, Schairer JR, Cao JJ, Keteyian SJ.
    Am Heart J; 2004 Nov 06; 148(5):910-4. PubMed ID: 15523326
    [Abstract] [Full Text] [Related]

  • 36. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate.
    Williams B, Lacy PS, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):705-13. PubMed ID: 19679248
    [Abstract] [Full Text] [Related]

  • 37. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M, Zacà V, Lombardi C, Bugatti S, Dei Cas L.
    G Ital Cardiol (Rome); 2010 Mar 18; 11(3):209-20. PubMed ID: 20550061
    [Abstract] [Full Text] [Related]

  • 38. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials.
    Cucherat M.
    Eur Heart J; 2007 Dec 18; 28(24):3012-9. PubMed ID: 17981830
    [Abstract] [Full Text] [Related]

  • 39. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 18; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 40. Heart rate and cardiovascular protection.
    Caetano J, Delgado Alves J.
    Eur J Intern Med; 2015 May 18; 26(4):217-22. PubMed ID: 25704330
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.